Condition: Arteriosclerosis · Peripheral Artery Disease · Chronic Limb Threatening Ischemia · Sponsor: Liyuan Hospital of Tongji Medical College, Huazhong University of Science and Technology
This study is a multicenter observational study designed to evaluate the the effectiveness and safety of drug-coated balloon (DCB) angioplasty for below the knee arterial lesions in patients critical with Limb Threatening Ischemia (CLTI).
This description comes directly from the study's public registry record.
Zibo Feng · 86-13545160302 · fengzibo@hust.edu.cn
Ye Du · 86-15827105515 · duye@hust.edu.cn
Always discuss trial participation with your own doctor first.
| Xuanwu Hospital Capital Medical University | Beijing, Beijing Municipality, China | Recruiting |
| Zibo Feng | Wuhan, Hubei, China | Recruiting |
| the second Affiliated Hospital of Medical College of Suzhou University | Suzhou, Jiangsu, China | Recruiting |
| Qingdao Haici hospital affiliated to Qingdao University | Qingdao, Shandong, China | Recruiting |
| Huashan Hospital, Fudan University | Shanghai, Shanghai Municipality, China | Recruiting |
| Renji Hospital of Shanghai Jiaotong University | Shanghai, Shanghai Municipality, China | Recruiting |
| Zhongshan Hospital of Fudan University | Shanghai, Shanghai Municipality, China | Recruiting |
| Hospital of Chengdu University of Traditional Chinese Medicine | Chengdu, Sichuan, China | Recruiting |
| Hangzhou First People's hospital of Medical College of Zhejiang University | Hangzhou, Zhejiang, China | Recruiting |
| the First Affiliated hospital of Medicine College of Zhejiang University | Hangzhou, Zhejiang, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05620095